J. Cownie

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

Amanda R. Kulick, M. Ladanyi, M. Berger, 2019, Nature Medicine.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

M. Berger, S. Loi, S. Chandarlapaty, 2018, Science Signaling.

6.5-Months-Olds' Perception of Goal-Directed, Animated Motion

E. Ray, A. Schlottmann, J. Cownie, 2006 .

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

Amanda R. Kulick, M. Ladanyi, M. Berger, 2019, Nature Network Boston.